Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. Here, we suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments.
Marketing of unproven stem cell-based interventions: A call to action / Sipp, D.; Caulfield, T.; Kaye, J.; Barfoot, J.; Blackburn, C.; Chan, S.; De Luca, M.; Kent, A.; Mccabe, C.; Munsie, M.; Sleeboom-Faulkner, M.; Sugarman, J.; Van Zimmeren, E.; Zarzeczny, A.; Rasko, J. E. J.. - In: SCIENCE TRANSLATIONAL MEDICINE. - ISSN 1946-6234. - 9:397(2017), pp. eaag0426-essg0426. [10.1126/scitranslmed.aag0426]
Marketing of unproven stem cell-based interventions: A call to action
De Luca M.;
2017
Abstract
Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. Here, we suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments.
| File | Dimensione | Formato | |
|---|---|---|---|
|
sipp2017.pdf
Accesso riservato
Tipologia:
Versione pubblicata dall'editore
Dimensione
256.28 kB
Formato
Adobe PDF
|
256.28 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
